EXHIBIT 99.4
                                                                    ------------

                      BOSTON SCIENTIFIC SUBMITS IDE TO FDA
                       FOR ITS NEW EXPRESS CORONARY STENT

                   COMPANY EXPECTS FIRST HUMAN IMPLANT IN MAY

Natick, MA (April 11, 2001) - Boston Scientific Corporation (NYSE: BSX) today
announced that it submitted an application to the U.S. Food and Drug
Administration for an Investigational Device Exemption (IDE) of its internally
developed Express coronary stent. Initiation of clinical trials in the United
States could begin as early as next month.

Boston Scientific's clinical study plan, which is subject to FDA approval, is
expected to enroll 450 patients at 25 sites throughout the U.S. It is designed
to demonstrate the safety and efficacy of the device for use in elective
coronary stenting and for the treatment of abrupt closure/threatened abrupt
closure (AC/TAC).

The Express stent is the company's newest internally developed coronary stent,
mounted on one of Boston Scientific's market-leading catheters. It is designed
to provide outstanding performance by optimizing flexibility, deliverability and
scaffolding characteristics.

"The submission of the IDE represents the achievement of a significant milestone
in the development of Boston Scientific's coronary stent program," said Jim
Tobin, President and Chief Executive Officer of Boston Scientific. "This
achievement brings us a large step closer to being able to provide physicians
with a new stent platform that is highly deliverable. Our teams working on this
project deserve enormous credit for the impressive progress they have made in
such a short period of time."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical
devices. The company's products are used in a broad range of interventional
medical specialties.

This press release contains forward-looking statements. The Company wishes to
caution the reader that actual results may differ from those discussed in the
forward-looking statements and may be adversely affected by, among other things,
risks inherent in commercialization of emerging technologies, physician
acceptance of new products, competitive offerings and other factors described in
the Company's filings with the Securities and Exchange Commission.


                                 CONTACT:    Milan Kofol 508-650-8569
                                             Investor Relations
                                             Boston Scientific Corporation

                                             Paul Donovan 508-650-8541
                                             Media Relations
                                             Boston Scientific Corporation